HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.

AbstractBACKGROUND AND PURPOSE:
The intention-to-treat analysis of data from the placebo-controlled Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial found 80 mg atorvastatin per day reduced the risk of stroke and major coronary events in patients with recent stroke or transient ischemic attack. This benefit was present despite only a 78% net difference in adherence to randomized treatment over the course of the trial. In this exploratory analysis, our aim was to evaluate the benefit and risks associated with achieving a >or=50% low-density lipoprotein cholesterol (LDL-C) reduction from baseline.
METHODS:
This post hoc analysis was based on 55,045 LDL-C measurements among the 4731 patients enrolled in SPARCL (average, 11.6 measurements per patient) during a mean follow-up of 4.9 years. At each postrandomization LDL-C assessment, percent change in LDL-C from baseline for each patient was classified as no change or increase from baseline (32.7% of measurements), <50% LDL-C reduction (39.4%), or >or=50% reduction (27.9%).
RESULTS:
Compared with no change or an increase in LDL-C, analysis of time-varying LDL-C change showed that patients with >or=50% LDL-C reduction had a 31% reduction in stroke risk (hazard ratio, 0.69, 95% CI, 0.55 to 0.87, P=0.0016), a 33% reduction in ischemic stroke (P=0.0018), no statistically significant increase in hemorrhagic stroke (P=0.8864), and a 37% reduction in major coronary events (P=0.0323). There was no increase in the incidence of myalgia or rhabdomyolysis. Persistent liver enzyme elevations were more frequent in the group with >or=50% LDL-C reduction.
CONCLUSIONS:
As compared with having no change or an increase in LDL-C, achieving a >or=50% lowering was associated with a greater reduction in the risk of stroke and major coronary events with no increase in brain hemorrhages.
AuthorsPierre Amarenco, Larry B Goldstein, Michael Szarek, Henrik Sillesen, Amy E Rudolph, Alfred Callahan 3rd, Michael Hennerici, Lisa Simunovic, Justin A Zivin, K Michael A Welch, SPARCL Investigators
JournalStroke (Stroke) Vol. 38 Issue 12 Pg. 3198-204 (Dec 2007) ISSN: 1524-4628 [Electronic] United States
PMID17962589 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Anticholesteremic Agents
  • Cholesterol, LDL
  • Lipids
Topics
  • Aged
  • Anticholesteremic Agents (therapeutic use)
  • Brain (pathology)
  • Cholesterol, LDL (metabolism)
  • Female
  • Follow-Up Studies
  • Humans
  • Ischemic Attack, Transient (blood, prevention & control)
  • Lipids (chemistry)
  • Male
  • Middle Aged
  • Risk
  • Stroke (blood, prevention & control)
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: